Literature DB >> 21221591

Macrophage activation syndrome in children with systemic onset juvenile idiopathic arthritis: clinical experience from northwest India.

Surjit Singh1, Shanmuganathan Chandrakasan, Jasmina Ahluwalia, Deepti Suri, Amit Rawat, Nishath Ahmed, Reena Das, M U S Sachdeva, Neelam Varma.   

Abstract

The objective of this study is to describe the clinical and laboratory features of macrophage activation syndrome (MAS) in systemic onset juvenile idiopathic arthritis (SOJIA) at a tertiary care center in northwest India. Review of medical records of all children with SOJIA admitted during the period January 1995-December 2008 in Pediatric Allergy and Immunology Unit, Advanced Pediatrics Centre, Postgraduate Institute of Medical Education and Research, Chandigarh, was done. Six patients (5 boys and 1 girl) with SOJIA and MAS were identified. Mean age at time of disease onset was 6.5 years. MAS was the presenting manifestation of SOJIA in 4 patients. Clinical manifestations included fever (6/6), clinical shock (6/6), encephalopathy (5/6), generalized lymphadenopathy (4/6), hepatosplenomegaly (3/6), jaundice and abdominal tenderness (3/6), cardiac involvement (3/6), and meningeal irritation (2/6). Laboratory findings at onset of MAS included decreasing total leukocyte and platelet counts, coagulopathy, elevated transaminases, hyponatremia, and lipid abnormalities. Hemophagocytosis was demonstrable in the bone marrow in 4 patients and in the lymph node in 1. For treatment, we used intravenous methylprednisolone (4/6), oral prednisolone (2/6), and intravenous immunoglobulin (2/6). Outcome was favorable in all patients except one who died of rapidly progressive disease. This paper describes the experience of JIA-related macrophage activation syndrome in a tertiary Indian center. We have shown that MAS can be the early presenting manifestation of evolving SOJIA. Early diagnosis and aggressive management can have a significant impact on the mortality associated with this syndrome. We stress on the role of glucocorticoids in the management of this condition and believe that glucocorticoids have a far more important role in the management of this condition than what has been previously reported.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21221591     DOI: 10.1007/s00296-010-1711-z

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   3.580


  25 in total

1.  Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders.

Authors:  S Sawhney; P Woo; K J Murray
Journal:  Arch Dis Child       Date:  2001-11       Impact factor: 3.791

2.  Macrophage activation syndrome in a patient with systemic onset rheumatoid arthritis: rescue with intravenous immunoglobulin therapy.

Authors:  Antonio G Tristano; Lady Casanova-Escalona; Alcira Torres; Martín A Rodríguez
Journal:  J Clin Rheumatol       Date:  2003-08       Impact factor: 3.517

3.  Hemophagocytosis accompanying typhoid fever.

Authors:  T M Fame; D Engelhard; H D Riley
Journal:  Pediatr Infect Dis       Date:  1986 May-Jun

4.  The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis.

Authors:  Jack Bleesing; Anne Prada; David M Siegel; Joyce Villanueva; Judyann Olson; Norman T Ilowite; Hermine I Brunner; Thomas Griffin; Thomas B Graham; David D Sherry; Murray H Passo; Athimalaipet V Ramanan; Alexandra Filipovich; Alexei A Grom
Journal:  Arthritis Rheum       Date:  2007-03

5.  [Macrophage activation syndrome associated with systemic juvenile idiopathic arthritis].

Authors:  Clóvis Artur A Silva; Carlos Henrique M Silva; Tereza Cristina M V Robazzi; Ana Paola N Lotito; Alfredo Mendroni Junior; Cristina M A Jacob; Maria Helena B Kiss
Journal:  J Pediatr (Rio J)       Date:  2004 Nov-Dec       Impact factor: 2.197

Review 6.  Macrophage activation syndrome in juvenile systemic lupus erythematosus: an under-recognized complication?

Authors:  A Pringe; L Trail; N Ruperto; A Buoncompagni; A Loy; L Breda; A Martini; A Ravelli
Journal:  Lupus       Date:  2007       Impact factor: 2.911

7.  Intravenous immunoglobulin therapy for severe arthritis associated with human parvovirus B19 infection.

Authors:  Eiichi Ogawa; Shigeru Otaguro; Masayuki Murata; Mosaburo Kainuma; Yasunori Sawayama; Norihiro Furusyo; Jun Hayashi
Journal:  J Infect Chemother       Date:  2008-10-21       Impact factor: 2.211

8.  Acute hemorrhagic, hepatic, and neurologic manifestations in juvenile rheumatoid arthritis: possible relationship to drugs or infection.

Authors:  M Hadchouel; A M Prieur; C Griscelli
Journal:  J Pediatr       Date:  1985-04       Impact factor: 4.406

9.  Reactive macrophage activation syndrome: a simple screening strategy and its potential in early treatment initiation.

Authors:  U Emmenegger; A Reimers; U Frey; Ch Fux; F Bihl; D Semela; P Cottagnoud; A Cerny; P J Spaeth; Klaus A Neftel
Journal:  Swiss Med Wkly       Date:  2002-05-04       Impact factor: 2.193

10.  Childhood macrophage activation syndrome differs from infection-associated hemophagocytosis syndrome in etiology and outcome in Taiwan.

Authors:  Hsin Hsu Chen; Ho Chang Kuo; Ling Wang; Hong Ren Yu; Jiun Min Shen; Kao Pin Kwang; Kuender D Yang
Journal:  J Microbiol Immunol Infect       Date:  2007-06       Impact factor: 4.399

View more
  7 in total

Review 1.  Anakinra treatment in macrophage activation syndrome: a single center experience and systemic review of literature.

Authors:  Hafize Emine Sönmez; Selcan Demir; Yelda Bilginer; Seza Özen
Journal:  Clin Rheumatol       Date:  2018-04-16       Impact factor: 2.980

2.  Safety of Intravenous Methylprednisolone in Refractory and Severe Pediatric Uveitis.

Authors:  Hashem H Ghoraba; Wataru Matsumiya; Hassan Khojasteh; Amir Akhavanrezayat; Irmak Karaca; Christopher Or; Negin Yavari; Sherin Lajevardi; Jaclyn Hwang; Cigdem Yasar; Diana Do; Quan Dong Nguyen
Journal:  Clin Ophthalmol       Date:  2022-05-31

3.  Macrophage activation syndrome in children with systemic juvenile idiopathic arthritis and systemic lupus erythematosus.

Authors:  Selin Aytaç; Ezgi Deniz Batu; Şule Ünal; Yelda Bilginer; Mualla Çetin; Murat Tuncer; Fatma Gümrük; Seza Özen
Journal:  Rheumatol Int       Date:  2016-08-10       Impact factor: 2.631

4.  Clinical analysis of macrophage activation syndrome in pediatric patients with autoimmune diseases.

Authors:  Cheng-I Lin; Hsin-Hui Yu; Jyh-Hong Lee; Li-Chieh Wang; Yu-Tsan Lin; Yao-Hsu Yang; Bor-Luen Chiang
Journal:  Clin Rheumatol       Date:  2012-05-22       Impact factor: 3.650

Review 5.  Macrophage activation syndrome: early diagnosis is key.

Authors:  Butsabong Lerkvaleekul; Soamarat Vilaiyuk
Journal:  Open Access Rheumatol       Date:  2018-08-31

Review 6.  Macrophage Activation Syndrome in Children: Diagnosis and Management.

Authors:  Narendra Kumar Bagri; Latika Gupta; Ethan S Sen; A V Ramanan
Journal:  Indian Pediatr       Date:  2021-03-26       Impact factor: 1.411

Review 7.  Evidence-based diagnosis and treatment of macrophage activation syndrome in systemic juvenile idiopathic arthritis.

Authors:  V Boom; J Anton; P Lahdenne; P Quartier; A Ravelli; N M Wulffraat; S J Vastert
Journal:  Pediatr Rheumatol Online J       Date:  2015-12-03       Impact factor: 3.054

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.